US Patent

US8052994 — 3â²-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene] hydrazino]-2â²-hydroxy-[1,1â²-biphenyl]-3-carboxylic acid bis-(monoethanolamine)

Method of Use · Assigned to GlaxoSmithKline LLC · Expires 2027-08-01 · 1y remaining

Vulnerability score 80/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects novel pharmaceutical compositions containing eltrombopag olamine and processes for preparing them.

USPTO Abstract

Disclosed are novel pharmaceutical compositions containing 3â²-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2â²-hydroxy-[1,1â²-biphenyl]-3-carboxylic acid bis-(monoethanolamine) (eltrombopag olamine) and processes for preparing the same.

Drugs covered by this patent

eltrombopag-olamine (ELTROMBOPAG OLAMINE)

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-1306`	—	eltrombopag-olamine
`U-1714`	—	eltrombopag-olamine
`U-1714`	—	eltrombopag-olamine
`U-1714`	—	eltrombopag-olamine

Patent Metadata

Patent number: US8052994
Jurisdiction: US
Classification: Method of Use
Expires: 2027-08-01
Drug substance claim: No
Drug product claim: Yes
Assignee: GlaxoSmithKline LLC
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.